Kunle Odunsi, MD, PhD, FRCOG, FACOG

PrintE-mail
Chair, Department of Gynecologic Oncology
Professor of Gynecologic Oncology, Division of Surgical Subspecialties, Department of Gynecologic Oncology
Research Program Director, Division of Gynecologic Oncology
Director, Center for Immunotherapy
Roswell Park Cancer Institute
Professor of Gynecology & Obstetrics
School of Medicine and Biomedical Sciences State University of New York at Buffalo
Director, US Cancer Vaccine Collaborative Program
Cancer Research Institute/Ludwig Institute for Cancer Research

Profile

Areas of Expertise: 
Cervical cancer
Ovarian cancer
Trophoblastic disease
Uterine cancer
Vaginal cancer
Vulvar cancer
Biography: 

Dr. Adekunle "Kunle" Odunsi is Chair of the Department of Gynecologic Oncology, Director of the Center for Immunotherapy and Co-Leader of the Tumor Immunology and Immunotherapy research program at Roswell Park Cancer Institute. He joined RPCI's staff in 2001 as an Attending Surgeon in the Division of Gynecologic Oncology, Department of Surgical Oncology. After earning his medical degree from the University of Ife, Ile-Ife, Nigeria, in 1984, Dr. Odunsi completed postgraduate training in Obstetrics and Gynecology at the Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK. He was admitted to the Royal College of Obstetricians and Gynecologists in 1991.

Dr. Odunsi completed a research fellowship in Molecular Oncology and earned his Ph.D. at the Imperial Cancer Research Fund Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK. Subsequently, he completed residency training in Obstetrics & Gynecology at the Yale University School of Medicine, New Haven, CT, and clinical fellowship in Gynecologic Oncology at RPCI. He is a Fellow of the Royal College of Obstetricians and Gynaecologists in the United Kingdom. He is also a Fellow of the American College of Obstetricians and Gynecologists.

Dr. Odunsi is licensed by New York State and certified in Obstetrics & Gynecology by the American Board of Obstetrics and Gynecology. He is also board certified in the sub-specialty of Gynecologic Oncology.

Dr. Odunsi’s research interests include the molecular characterization of tumor antigens in ovarian cancer and their application to the development of vaccine therapies for the disease. 

Dr. Odunsi has authored or co-authored more than 140 journal publications and  book chapters. He is Associate Editor for BMC Cancer. He also is an Ad Hoc Reviewer for the American Journal of Obstetrics and Gynecology, BLOOD, BMC Cancer, Cancer Immunity, Cancer Immunology Immunotherapy, Cancer Letters, Cancer Research, Clinical Cancer Research, Expert Opinion on Biological Therapy, Fertility and Sterility, Future Oncology, Gynecologic Oncology, International Journal of Cancer, Journal of Clinical Pathology, Journal of the Society for Gynecologic Investigation, The Lancet, Mayo Clinic Proceedings,  Molecular Cancer Therapeutics, Oncogene, Oncology PLoS ONE and the Proceedings of the National Academy of Sciences, U.S.A.

Research

Research Interests: 
Molecular characterization of tumor antigens in ovarian cancer
Development of cancer vaccine therapies
Early detection of ovarian cancer
Research Profile: 
Research Profile Link

Background Information

Education and Training: 
MD - University of Ife, College Of Health Sciences, Ile-Ife, Nigeria
MRCOG - The Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK
PhD - Imperial Cancer Research Fund Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, Oxfordshire, UK
Residency: 
Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT
Board Certification: 
Obstetrics & Gynecology, American Board of Obstetrics & Gynecology
Gynecologic Oncology, American Board of Obstetrics & Gynecology
Fellowships: 
Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY

Publications

Publications: 
  • Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future oncology (London, England) 2010; 6(5):717-732
  • Cheng L, Lu W, Kulkarni B, Pejovic T, Yan X, Chiang J-H, Hood L, Odunsi K, Lin B. Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies. Gynecologic oncology 2010; 117(2):159-169
  • Ferchichi I, Stambouli N, Marrackchi R, Arlot Y, Prigen C, Fadiel A, Odunsi K, Elgaaied ABA, Hamza A. Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase. Journal of physical chemistry. B 2010; 114(3):1486-1497
  • J�ger D, Gnjatic S, Odunsi K, Old LJ, Ritter G, Andrews C, Chen Y-T, Zörnig I, Halama N, Murray A, Frei C, Brors B, Giese NA, Büchler MW, Ritter E, Jäger D. Seromic profiling of ovarian and pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America 2010; 107(11):5088-5093
  • Kesterson JP, Odunsi K, Lele S. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy 2010; 56(2):108-111
  • Li Q, Eppolito C, Odunsi K, Shrikant PA. Antigen-induced Erk1/2 activation regulates Ets-1-mediated sensitization of CD8+ T cells for IL-12 responses. Journal of leukocyte biology 2010; 87(2):257-263
  • Matsuzaki J, Old LJ, Shrikant P, Lele S, Qian F, Eppolito C, Tsuji T, Miller A, Beck A, Mhawech-Fauceglia P, Gnjatic S, Odunsi K. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2010; 107(17):7875-7880
  • , McCloskey SA, Tchabo NE, Malhotra HK, Odunsi K, Rodabaugh K, Singhal P, Lele S, Jaggernauth W. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecologic oncology 2010; 116(3):404-407
  • Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, Odunsi K, Cheney RT. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. American journal of clinical pathology 2010; 133(6):899-908
  • Paczos TA, Ackers S, Odunsi K, Lele S, Mhawech-Fauceglia P. Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy. International journal of gynecological pathology 2010; 29(2):193-196
  • Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010; 32(1):67-78
  • Shen J, DiCioccio R, Odunsi K, Lele SB, Zhao H. Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC cancer 2010; 10 :47
  • DuPont NC, Guru KA, Iskander GB, Odunsi K, Lele SB, Rodabaugh KJ. Instituting a robot-assisted surgery programme at a tertiary care cancer centre. International journal of medical robotics and computer assisted surgery 2010; 6(3):330-333
  • Godoy HE, Mhawech-Fauceglia P, Beck Amy, Miller A, Lele S, Odunsi K. Expression of poly(adenosine diphosphate-ribose) polymerase (PARP) and p53 in epithelial ovarian cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:192
  • Kesterson J, Weiss J, Rodabaugh K, Nowell S, Odunsi K, Zirpoli G, Grasela M, Sucheston L, Moysich K. An assessment of the concordance of pharmacogenetic polymorphisms between tumor and germline specimens in patients with ovarian cancer. Gynecologic oncology 2010; 116(3 Suppl. 1):348
  • Moysich KB, Nesline M, Davis W, Wallace P, Grasela M, Hampras S, Chennamaneni R, Odunsi K. The influence of regulatory T cells on breast cancer risk and clinical characteristics. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:1288
  • Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, Karpf AR. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer immunity 2010; 10:6
  • Godoy H, Eppolito C, Balu-Iyer S, Lele S, Odunsi K. Dendritic cells loaded with WT-1 and lipid A in a cationic liposome promote tumor immunity in a mouse model of ovarian cancer. Reproductive sciences (Thousand Oaks, Calif.) 2010; 17(3 Suppl.):1013
  • Batt RE , Mhawech-Fauceglia P , Odunsi K , Yeh J. Pathogenesis of mediastinal paravertebral mullerian cysts of Hattori: developmental endosalpingiosis-mullerianosis. International journal of gynecological pathology 2010; 29(6):546-551
  • Hogdall C , Hillemanns P , Durst M , Runnebaum I , Thompson PJ , Carney ME , Goodman MT , Lurie G , Wang-Gohrke S , Hein R , Chang-Claude J , Rossing MA , Cushing-Haugen KL , Doerk T , Antonenkova N , Bogdanova N , Gross J , Karlan BY , Ness RB , Edwards RP , Odunsi K , Moyisch KB , Baker JA , Modugno F , Heikkinenen T , Butzow R , Nevanlinna H , Leminen A , Doherty J , Chen C , Ekici AB , Chen X , Johnatty SE , Webb PM , Beesley J , Chanock S , Garcia-Closas M , Sellers T , Easton DF , Berchuck A , Chenevix-Trench G , Pharoah PDP , Thiel FC , Beckmann MW , Fasching PA , Rafnar T , Besenbacher S , Sulem P , Stefansson K , Birrer MJ , Terry KL , Hernandez D , Cramer DW , Vergote I , Amant F , Lambrechts D , Despierre E , Gayther SA, Bolton KL , Brewster W , Anton-Culver H , Ziogas A , Narod SA , Levine DA , Kaye SB , Brown R , Paul J , Flanagan J , Sieh W , McGuire V , Whittemore AS , Wu AH , Pearce CL , Stram DO , Tyrer J , Song H , Ramus SJ , Notaridou M , Jones C , Sher T , Gentry-Maharaj A , Wozniak E , Tsai Y-Y , Weidhaas J , Paik D , Van Den Berg DJ , Campbell I , Gore ME , Tomlinson I , Palmieri RT , Moorman PG , Schildkraut J , Iversen ES , Phelan C , Vierkant RA , Cunningham JM , Goode EL , Fridley BL , Kruger-Kjaer S , Blaeker J , Houlston R , Van Altena AM , Aben KKH , Lissowska J , Yang HP , Medrek K , Gronwald J , Lubinski J , Jakubowska A , Le ND , Cook LS , Kelemen LE , Brook-Wilson A , Massuger LFAG , Kiemeney LA , Hogdall E . Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature genetics 2010; 42(10):880-884
  • Caballero OL , Pejovic T , Odunsi K , Brasseur F , van den Eynde BJ , Old LJ , Lu X , Cebon J , Strausberg RL , Liu C , Wolchok JD , Speiser D , Zhao Q , Rimoldi D , Stevenson BJ , Svobodova S , Devalle S , Rohrig UF , Pagotto A , Michielin O , Simpson AJ. Frequent MAGE mutations in human melanoma. PloS one 2010; 5(9):e12773
  • Mhawech-Fauceglia P , Herrmann RF , Kesterson J , Izevbaye I , Lele S , Odunsi K. Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium. European journal of surgical oncology 2010; 36(12):1195-1201
  • Mhawech-Fauceglia P , Wang D , Kesterson J , Clark K , Monhollen L , Odunsi K , Lele S , Liu S. Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PloS one 2010; 5(11):e15415
  • Wadle A , Cerundolo V , Knuth A , Shrikant PA , Odunsi K , Shiku H , Jager E , Karbach J , Kleber S , Fischer E , Wullner B , Neumann F , Held G , Nishikawa H , Strahl S , Mischo A , Renner C. NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. Yeast (Chichester, England) 2010; 27(11):919-931
  • Karpf AR. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer immunity 2010; 10 :6
  • Britten CM, Hoos A, Old L, Pride M, Odunsi K, Maecker H, Kalos M, Clay TM, Ben-Porat L, Janetzki S, Romero P. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer immunology, immunotherapy : CII 2009; 58(10):1701-1713
  • Chen Y-T, Simpson AJ, Jin B-Q, Song C-J, Altorki NK, Odunsi K, Mhawech-Fauceglia P, Shin SJ, Lee P, Hsu M, Old LJ. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. International journal of cancer 2009; 124(12):2893-2898
  • Leveque L, Deknuydt F, Bioley G, Old LJ, Matsuzaki J, Odunsi K, Ayyoub M, Valmori D. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. Journal of immunotherapy (Hagerstown, Md. : 1997) 2009; 32(2):101-108
  • Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, Odunsi K. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics. Clinical applications 2009; 3(7):853-861
  • Mhawech-Fauceglia P, Herrmann FR, Andrews C, South S, Beck A, Lele S, Odunsi K. 14-3-3sigma Expression and Prognostic Value in Patients with Epithelial Ovarian Carcinoma: a High Throughput Tissue Microarray Analysis. European journal of surgical oncology 2009; 35(7):763-767
  • Mhawech-Fauceglia P, Herrmann FR, Wagner H, Godoy H, Odunsi K, Cheney RT, Lele S. Submission of the entire lymph node dissection for histologic examination in gynecologic-oncologic specimens. Clinical and pathologic relevance. Gynecologic oncology 2009; 115(3):354-356
  • Pejovic T, Caballero O, Huang J, Levy S, Tsiamouri A, Cain J, Bagby GC, Strausberg RL, Simpson AJ, Cappuccini F, Djilas J, Tarumi Y, Pande NT, Mori M, Mhawech-Fauceglia P, Harrington C, Mongoue-Tchokote S, Dim D, Andrews C, Beck A, Odunsi KO. Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. Translational oncology 2009; 2(4):341-349
  • Qian F, Old LJ, Shrikant P, Lele S, Moysich K, Cheney R, Liao J, Beck A, Frederick PJ, Ayyoub M, Valmori D, Matsuzaki J, Andrews C, Tario Jr JD, Mhawech-Fauceglia P, Wallace PK, Villella J, Odunsi K. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer research 2009; 69(13):5498-5504
  • Rai H, Odunsi K, Kesterson J, Morrison C, Chan A, Mhawech-Fauceglia P. Epithelioid sarcoma of the vulva in a 17-year-old pregnant woman. Applied immunohistochemistry and molecular morphology : AIMM 2009; 17(3):270-273
  • Simpson-Abelson MR, Balu-Iyer S, Kelleher Jr RJ, Loyall JL, Yokota SJ, Demmy TL, Odunsi K, Iyer V, Pang WM, Purohit VS, Bankert RB. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clinical immunology (Orlando, Fla.) 2009; 132(1):71-82
  • Sukumaran DK, Garcia E, Hua J, Tabaczynski W, Odunsi K, Andrews C, Szyperski T. Standard operating procedure for metabonomics studies of blood serum and plasma samples using a 1H-NMR micro-flow probe. Magnetic resonance in chemistry : MRC 2009; 47 Suppl. 1:S81-S85
  • Tayo BO, DiCioccio RA, Liang Y, Trevisan M, Cooper RS, Lele S, Sucheston L, Piver SM, Odunsi K. Complex segregation analysis of pedigrees from the Gilda Radner Familial Ovarian Cancer Registry reveals evidence for mendelian dominant inheritance. PloS one 2009; 4(6):e5939
  • Tchabo NE, McCloskey S, Mashtare TL, Andrews C, Singh AK, Mhawech-Fauceglia P, Odunsi K, Lele S, Jaggernauth W. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. Gynecologic oncology 2009; 115(2):249-256
  • Tchabo NE, Old LJ, Lele S, Andrews C, Liao J, Miliotto AJ, Beck AF, Villella J, Caballero OL, Mhawech-Fauceglia P, Odunsi K. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer immunity 2009; 9:6
  • Britten CM, Hoos A, Romero P, Roep BO, Pawelec G, Old LJ, Odunsi K, O'Donnell-Tormey J, Melief CJM, Maecker HT, Levitsky HI, Kalos M, Huber C, van der Burg SH, Janetzki S, Davis MM. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer immunology, immunotherapy : CII 2011; 60(1):15-22
  • Godoy H, Mhawech-Fauceglia P, Beck A, Miller A, Lele S, Odunsi K. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. International journal of gynecological pathology 2011; 30(2):139-144
  • Odunsi KO. The race between ovarian cancer and immunity: How hormones and inhibitory molecules set the pace. Biology of reproduction 2010; 83:105
  • Tsuji T, Ritter G, Old LJ, Odunsi K, Keler T, He L-Z, Vitale L, Ramakrishna V, Kelly MP, Matsuzaki J, Gnjatic S. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. Journal of immunology (Baltimore, Md. : 1950) 2011; 186(2):1218-1227
  • Akers S, Moysich K, Zhang W, Link P, Miller A, Lele S, Odunsi K, Karpf A. Association between global DNA hypomethylation in leukocytes and risk of ovarian cancer. Gynecologic oncology 2011; 121(1 Suppl.):100
  • Garcia E, Andrews C, Hua J, Kim HL, Sukumaran DK, Szyperski T, Odunsi K. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. Journal of proteome research 2011; 10(4):1765-1771
  • Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, Shrikant PA. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 2011; 34(4):541-553
  • Shroff S, Wang D, Kesterson J, Liu S, Odunsi K, Mhawech-Fauceglia P. The Expression and Value of Aldolase in Endometrial Cancer and the Role of Clotrimazole in Endometrial Cancer Cell Viability and Morphology. Laboratory investigation 2011; 91(Suppl. 1):1131
  • Syriac S, Wang D, Kesterson J, Odunsi K, Lele S, Liu S, Mhawech-Fauceglia P. Differentially Expressed Genes in Early Stages Uterine Serous Carcinomas in Comparison to G3 and G1 Endometrioid Adenocarcinoma. Laboratory investigation 2011; 91(Suppl. 1):1139
  • Woloszynska-Read A, Odunsi K, Godley LA, Ostler KR, Akers SN, Collamat G, Mhawech-Fauceglia P, Link PA, Yu J, Zhang W, Karpf AR. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clinical cancer research 2011; 17(8):2170-2180
  • Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. International journal of cancer 2008; 123(6):1376-1384
  • Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer immunology, immunotherapy : CII 2008; 57(8):1185-1195
  • Mhawech-Fauceglia P, Allal A, Odunsi K, Andrews C, Herrmann FR, Huard B. Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas. European journal of cancer (Oxford, England : 1990) 2008; 44(15):2097-2100
  • Mhawech-Fauceglia P, Herrmann F, Bshara W, Zhang S, Penetrante R, Lele S, Odunsi K, Rodabaugh K. Intraobserver and interobserver variability in distinguishing between endocervical and endometrial adenocarcinoma on problematic cases of cervical curettings. International journal of gynecological pathology 2008; 27(3):431-436
  • Mhawech-Fauceglia P, Odunsi K, Dim D, Nowak N, Lele S, Cheney RT, Pejovic T. Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: mystery resolved? . International journal of gynecological pathology 2008; 27(4):539-546
  • Mhawech-Fauceglia P, Rai H, Nowak N, Cheney RT, Rodabaugh K, Lele S, Odunsi K. The use of array-based comparative genomic hybridization (a-CGH) to distinguish metastatic from primary synchronous carcinomas of the ovary and the uterus. Histopathology 2008; 53(4):490-495
  • Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(40):15505-15510
  • Odunsi K, Sabbatini P. Harnessing the immune system for ovarian cancer therapy. American journal of reproductive immunology (New York, N.Y. : 1989) 2008; 59(1):62-74
  • Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008; 29(10):1963-1966
  • Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, Old LJ, Valmori D, Ayyoub M. Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clinical immunology (Orlando, Fla.) 2008; 126(3):291-302
  • Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clinical cancer research 2008; 14(11):3283-3290
  • Yin BW, Old LJ, Lloyd KO, Odunsi K, Jungbluth AA, Filonenko V, Hellman U, Souchelnytskyi S, Bhaskaran N, Gryshkova V, Gout I, Caballero OL, Chua R, Kiyamova R, Ritter G. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer immunity 2008; 8:3
  • Aikhionbare FO, Mehrabi S, Kumaresan K, Zavareh M, Olatinwo M, Odunsi K, Partridge E. Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. Journal of carcinogenesis 2007; 6:1
  • Mhawech-Fauceglia P, Mhawech-Fauceglia P, Herrmann FR, Bshara W, Odunsi K, Terracciano L, Sauter G, Cheney RT, Groth J, Penetrante R. Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. Journal of clinical pathology 2007; 60(6):694-700
  • Odunsi K, Old LJ. Tumor infiltrating lymphocytes: Indicators of tumor-related immune responses. Cancer immunity 2007; 7:3
  • Odunsi K, Old LJ, Shrikant P, Lele S, Rodabaugh K, Thomas B, Villella J, Ritter G, Pan L, Hoffman EW, Andrews C, Mhawech-Fauceglia P, Matsuzaki J, Qian F, Gnjatic S. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2007; 104(31):12837-12842
  • Sabbatini P, Odunsi K. Immunologic approaches to ovarian cancer treatment. Journal of clinical oncology 2007; 25(20):2884-2893
  • Shamshirsaz AA, Withiam-Leitch M, Odunsi K, Baker T, Frederick PJ, Lele S. Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review. Gynecologic oncology 2007; 104(3):757-760
  • Sharma S, Tammela J, Wang X, Arnouk H, Driscoll D, Mhawech-Fauceglia P, Lele S, Kazim AL, Odunsi K. Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells. Clinical cancer research 2007; 13(19):5889-5896
  • Villella J, Herrmann FR, Kaul S, Lele S, Marchetti D, Natiella J, Odunsi K, Mhawech-Fauceglia P. Clinical and pathological predictive factors in women with adult-type granulosa cell tumor of the ovary. International journal of gynecological pathology 2007; 26(2):154-159
  • Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer immunity 2007; 7:21
  • Mhawech-Fauceglia P, Pejovic T, Dim D, Fang X, Conroy J, Lele S, Cheney R, Odunsi K. Array-based comparative genomic hybridization (aCGH) analysis is a useful tool for distinguishing primary pulmonary from metastatic neuroendocrine carcinoma to the lung. Applied immunohistochemistry and molecular morphology : AIMM 2008; 16(3):291-295
  • Mhawech-Fauceglia P, Herrmann F, Lele S, Higgs D, South S, Schwaller J, Andrews C, Bshara W, Smiraglia DJ, Odunsi K. Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer epidemiology, biomarkers and prevention 2008; 17(3):571-577
  • Moysich KB, Baker JA, Menezes RJ, Jayaprakash V, Rodabaugh KJ, Odunsi K, Beehler GP, McCann SE, Villella JA. Usual adult body mass index is not predictive of ovarian cancer survival. Cancer epidemiology, biomarkers and prevention 2007; 16(3):626-628
  • Attig S, Romero P, Hoos A, Odunsi K, Yuan J, Clay T, McNeil L, Pride M, Kalos M, Janetzki S, Price L, Britten CM. A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. Journal of translational medicine 2011; 9:108
  • Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher Jr RJ, Barnas JL, Simpson-Abelson M, Parsons R, Yokota SJ. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PloS one 2011; 6(9):e24420
  • Huang RS, Fridley BL, Hogdall E, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, DeFazio A, Chenevix-Trench G, Vierkant RA, Goode EL, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, MacGregor S, Dolan ME. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clinical cancer research 2011; 17(16):5490-5500
  • Tsuji T, Matsuzaki J, Ritter E, Miliotto A, Ritter G, Odunsi K, Old LJ, Gnjatic S. Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. PloS one 2011; 6(8):e23651
  • Godoy HE, Kesterson JP, Eppolito C, Vethanayagam RR, Grimm MJ, Abrams S, Lele S, Segal BH, Odunsi K. NADPH Oxidase Modulates the Development of Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer Tumor-Bearing Hosts. Reproductive sciences (Thousand Oaks, Calif.) 2011; 18(3):290A
  • Mach C, Kim J, Zighelboim I, Goodfellow P, Odunsi K, Gunaratne P, Hawkins S, Anderson ML. Next Generation Sequencing Identifies miR-143 as a Putative Tumor Suppressor in Uterine Papillary Serous Carcinoma. Reproductive sciences (Thousand Oaks, Calif.) 2011; 18(3):290A
  • Berinstein NL, Morse M, Kaufman H, Nemunaitis JJ, Odunsi K, Chatta GS, Weir G, MacDonald L, Stanford M, Karkada M, Nigam R, Mansour M. A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e13050
  • Chan A, Bshara W, Odunsi K, Pejovic T, Mhawech-Fauceglia P. Clinico-pathologic features of female genital tract neuroendocrine carcinoma: A series study of 25 cases from two institutes. Laboratory investigation 2008; 88(Suppl. 1):199A (Abstract #912)
  • Ghadersohi A, Odunsi K, Fayazi Z, Zhang S, Azrak RG, Pan D, Keitz B, Bundy BN, Rustum YM, Li F. Prostate-derived Ets transcription Factor(PDEF) is a favorable prognostic marker for ovarian cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:403
  • Higgs D, Smiraglia D, Odunsi K, Herrmana F, Mhawech-Fauceglia P. Epigenetic mechanism is responsible for downregulation of prostate-specific membrane antigen (PSMA) in a subset of endometrial carcinomas. Laboratory investigation 2008; 88(Suppl. 1):206A (Abstract #941)
  • Jaggernauth WA, Tchabo N, Yang G, Yap J, Odunsi K, Rodabaugh K, Lele S, Singh A, Mc Closkey S. High distant failure rate despite good local control in high risk early stage endometrial cancer. International journal of radiation oncology, biology, physics 2008; 72(1 Suppl.):S366
  • Kesterson J, Lele SB, Odunsi KO, Shrikant P. Indoleamine 2,3-dioxygenase inhibition abrogates induction of regulatory T cells and promotes survival of ovarian tumor-bearing hosts. Gynecologic oncology 2009; 112(2 Suppl. 1):220
  • Mhawech-Fauceglia P, Bshara W, South S, Andrews C, Lele S, Odunsi K. PSMA mRNA and protein expression as potential prognostic markers in endometrial adenocarcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:95-96
  • Moysich KB, Ness R, Zirpoli G, Modugno F, Rodabaugh K, Baker JA, Odunsi K. Genetic variability in regulatory T (Treg) cell function in ovarian carcinogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:586-587
  • Moysich KB, Weiss J, Baker J, Davis W, Carter L, Odunsi K. High concordance between pharmacogenetic analysis of tumor and blood samples from patients with ovarian cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:812
  • Odunsi K, Ghamande S, Macfee M, Yu AYC, Lele SB, Rodabaugh KJ, Thomas B, Zamboni WC. A phase II, pharmacokinetic (PK), and pharmacodynamic (PD) study of weekly docetaxel (DOC) in patients with platinum-resistant ovarian cancer. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e16531
  • Odunsi K, Kesterson J, Qian F, Lele S, Shrikant P. Inhibition of IDO Abrogates Induction of Tregs and Promotes Survival of Ovarian Tumor Bearing Hosts. Reproductive sciences (Thousand Oaks, Calif.) 2009; 16(3 Suppl.):71
  • Odunsi K, Kowalski D, Mhawech-Fauceglia P, Andrews C, Lele S, Huang RY. Inhibition of Serine-Arginine Protein Kinase 1 (SRPK1) Overcomes Platinum Resistance in Ovarian Cancer. Reproductive sciences (Thousand Oaks, Calif.) 2009; 16(3 Suppl.):283
  • Odunsi K, Qian F, Villella J, Mhawech-Fauceglia P, Andrews C, Matsuzaki J, Frederick PJ, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ. Tryptophan degradation by indoleamine 2,3-dioxygenase promotes preferential accumulation of CD4(+)CD25(high)FOXP3(+) regulatory T cells in human ovarian cancer. Gynecologic oncology 2008; 108(3 Suppl. 1):338
  • Rai G, Kunle O, Lele S, Mhawech-Fauceglia P. A molecular genetic approach using array comparative genomic hybridization (aCGH) analysis in distinguishing synchronous versus metastatic carcinoma arising concurrently in the ovary and the endometrium. Laboratory investigation 2008; 88(Suppl. 1):220A (Abstract #1005)
  • Simpson-Abelson MR, Broderick L, Yokota SJ, Odunsi RB, Conway TF, Kelleher RJ, Bankert RB. Re-activation of memory T cells in the microenvironment of human tumors. Journal of immunotherapy (Hagerstown, Md. : 1997) 2007; 30(8):885
  • Singhal P, Mischo A, Li QS, Eppolito C, Tsuji M, Franke M, Lele S, Odunsi K, Shrikant P. The natural killer T-cell ligand alpha-C-galactosylceramide promotes ovarian cancer survival by dual regulation of the adaptive host immunity. Gynecologic oncology 2007; 104(3 Suppl. 1):S21-S22
  • Singhal P, Villella J, Andrews C, Lele S, Odunsi K. BORIS and FATE co-expression is a prognostic indicator in patients with epithelial ovarian cancer. Gynecologic oncology 2008; 108(3 Suppl. 1):195
  • Singhal PK, Shahzad MM, Odunsi KO, Lele SB. Platinum, adriamycin and VP-16 versus paclitaxel and carboplatin for treatment of advanced or recurrent endometrial carcinoma. Gynecologic oncology 2009; 112(2 Suppl. 1):121
  • South SA, Asubonten KO, Andrews C, Rodabaugh K, Odunsi K, Lele S. Weight loss after surgery impacts overall survival in epithelial ovarian cancer. Gynecologic oncology 2008; 108(3 Suppl. 1):347
  • Tchabo NE, Cabellero O, Mhawech-Fauceglia P, Andrews C, Lele SB, Odunsi KO. Developmentally restricted differentiation antigens in ovarian cancer. Gynecologic oncology 2009; 112(2 Suppl. 1):364
  • Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Epigenetic regulation of NY-ESO-1 in ovarian cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:679
  • Riebandt G, Rodabaugh KJ, Pietkiewicz J, Fong MK, Groman AE, Lele SB, Odunsi K, Akers S. Prospective analysis of chemotherapy-induced neuropathy in patients with gynecologic malignancies : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e19737
  • Agnani D, Camacho-Vanegas O, Camacho C, Lele S, Odunsi K, Cohen S, Dottino P, Martignetti JA. Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. Journal of ovarian research 2011; 4:18
  • Mhawech-Fauceglia P, Wang D, Kesterson J, Beck A, de Mesy Bentley KL, Shroff S, Syriac S, Frederick P, Liu S, Odunsi K. Aldolase mRNA expression in endometrial cancer and the role of clotrimazole in endometrial cancer cell viability and morphology. Histopathology 2011; 59(5):1015-1018
  • Mhawech-Fauceglia P, Wang D, Syriac S, Godoy H, Dupont N, Liu S, Odunsi K. Synuclein-gamma (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma. Gynecologic oncology 2012; 124(1):148-152
  • Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment. Cancer research 2011; 71(24):7463-7470
  • Griffiths EA, Karpf AR, Odunsi K, James SR, Beck AF, Wetzler M, Ford LA. Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo. Blood 2011; 118(21):1049
  • Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benitez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB, HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C, EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schonbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L, GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Canadas C, Heikkinen T, Heikkila P, Aittomaki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S, kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K, SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC, Moysich K, Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer epidemiology, biomarkers and prevention 2012; 21(1):134-147
  • Shen J, Wang D, Gregory SR, Medico L, Hu Q, Yan L, Odunsi K, Lele SB, Ambrosone CB, Liu S, Zhao H. Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer. Carcinogenesis 2012; 33(3):604-612
  • Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL for OCGN, Ozcelik H, Mulligan AM, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P for SWE-BRCA, Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Gorski B, Osorio A, Duran M, Tejada MI, Benitez J, Hamann U, Hogervorst FB for HEBON, van Os TA, van Leeuwen FE, Meijers-Heijboer HE, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems MG, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE for EMBRACE, Bove B, Godwin AK, Stoppa-Lyonnet D for GEMO Study Collaborators, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Leone M, Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry M, Chung WK, John EM, Miron A, Southey MC, Hopper JL, Goldgar DE, Singer CF, Rappaport C, Tea MK, Fink-Retter A, Hansen TV, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson ME, Piedmonte M, Phillips K, Basil J, Rubinstein WS, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PP, Odunsi KO, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz MD, Spurdle AB, Neuhausen SL, Ding YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G for kConFab investigators, Offit K, Simard J on behalf of the Consortium of Investigators of Modifiers of BRCA1/2, for kConFab investigators, on behalf of the Consortium of Investigators of Modifiers of BRCA1/2. Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer epidemiology, biomarkers and prevention 2012; 21(4):645-657
  • Huang R-Y, Odunsi K, Wong MKK. Identification of factors secreted by melanoma exhibiting propensity for lung metastases. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5170
  • Akers S, Khulpateea B, Groman A, Kesterson J, Odunsi K, Lele S, Frederick P. Adjuvant treatment for uterine leiomyosarcoma. Gynecologic oncology 2012; 125(Suppl. 1):S159
  • Godoy H, Vaddadi P, Cooper M, Frederick P, Odunsi K, Lele S. Photodynamic therapy effectively palliates gynecologic malignancies. Gynecologic oncology 2012; 125(Suppl. 1):S81
  • Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, Shrikant PA. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. Journal of immunology (Baltimore, Md. : 1950) 2012; 188(7):3080-3087
  • Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, DuPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jager E. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(15):5797-5802
  • Simons E, Kiet T, Amanam I, Ho M, Fuh J, Fuh K, Kapp D, Odunsi K, Chan J. Immune biomarkers associated with response to intra-peritoneal chemotherapy in ovarian cancer. Gynecologic oncology 2012; 125(Suppl. 1):S141
  • Simons E, Kiet T, Amanam I, Ho M, Fuh J, Fuh K, Kapp D, Odunsi K, Chan J. Immune biomarkers predictive of survival in epithelial ovarian cancer. Gynecologic oncology 2012; 125(Suppl. 1):S45-S46
  • Simons E, Kiet T, Amanam I, Ho M, Fuh J, Fuh K, Kapp D, Odunsi K, Chan J. Immune signatures predictive of optimal cytoreduction in ovarian cancer. Gynecologic oncology 2012; 125(Suppl. 1):S46
  • Tsuji T, Matsuzaki J, Caballero OL, Jungbluth AA, Ritter G, Odunsi K, Old LJ, Gnjatic S. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. Journal of immunology (Baltimore, Md. : 1950) 2012; 188(8):3851-3858
  • Vaddadi P, Godoy H, Kesterson J, Tolentino J, Frederick P, Dupont N, Lele S, Odunsi K. Identification of a subset of stage IV ovarian carinomas with improved overall survival. Gynecologic oncology 2012; 125(Suppl. 1):S102
  • Ademuyiwa FO, Bshara W, Attwood K, Edge SB, Ambrosone CB, Morrison CD, Ritter G, Miliotto A, Gnjatic S, Odunsi K. Immunogenicity of NY-ESO-1 cancer testis antigen in triple-negative breast cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e11563
  • Tykodi SS, Brahmer JR, Hwu W-J, Chow LQ, Topalian SL, Hwu P, Odunsi K, Camacho LH, Kauh JS, Pitot HC, Hamid O, Pardoll DM, Agrawal S, Parker S, Goldberg S, Gupta AK, Wigginton J. PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #2510
  • Odunsi K. Cancer diagnostics using 1H-NMR-based metabonomics. Ernst Schering Foundation symposium proceedings 2008; 2007(4):205-226
  • Singhal P, Tchabo NE, Odunsi K. Immunologic markers of cancer progression and prognosis. Expert opinion on medical diagnostics 2007; 1(4):439-450
  • Berinstein NL, Karkada M, Nigam R, Morse M, Nemunaitis JJ, Chatta GS, Kaufman H, Odunsi K, Weir G, MacDonald L, Stanford M, Mansour M. Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #2588
  • Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England journal of medicine 2012; 366(26):2455-2465
  • Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJM, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff THM, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012; 37(1):1-2
  • Kim K-M, Song M-H, Kim M-J, Daudi S, Miliotto A, Old L, Odunsi K, Lee S-Y. A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation. International journal of oncology 2012; 41(3):1139-1147
  • Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, Odunsi K, Valmori D, Ayyoub M. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer research 2012; 72(17):4351-4360
  • Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, Odunsi K, Creighton CJ, Lev DC, Anderson ML. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clinical cancer research 2012; 18(12):3352-3365
  • Ademuyiwa FO, Bshara W, Attwood K, Morrison C, 4533, Ambrosone CB, O'Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PloS one 2012; 7(6):e38783
  • Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen XQ, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, Loman N, Harbst K, Lindblom A, Arver B, Rosenquist R, Karlsson P, Nathanson K, Domchek S, Rebbeck T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowowcka-Perlowska E, Osorio A, Duran M, Andres R, Benitez J, Hamann U, Hogervorst FB, van Os TA, Verhoef S, Meijers-Heijboer HEJ, Wijnen J, Garcia EBG, Ligtenberg MJ, Kriege M, Collee M, Ausems MGEM, Oosterwijk JC, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Rogers MT, Donaldson A, Dorkins H, Godwin AK, Bove B, Stoppa-Lyonnet D, Houdayer C, Buecher B, de Pauw A, Mazoyer S, Calender A, Leone M, Bressac-de Paillerets B, Caron O, Sobol H, Frenay M, Prieur F, Ferrer SF, Mortemousque I, Buys S, Daly M, Miron A, Terry MB, Hopper JL, John EM, Southey M, Goldgar D, Singer CF, Fink-Retter A, Tea MK, Kaulich DG, Hansen TVO, Nielsen FC, Barkardottir RB, Gaudet M, Kirchhoff T, Joseph V, Dutra-Clarke A, Offit K, Piedmonte M, Kirk J, Cohn D, Hurteau J, Byron J, Fiorica J, Toland AE, Montagna M, Oliani C, Imyanitov E, Isaacs C, Tihomirova L, Blanco I, Lazaro C, Teule A, Del Valle J, Gayther SA, Odunsi K, Gross J, Karlan BY, Olah E, Teo SH, Ganz PA, Beattie MS, Dorfling CM, van Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schafer D, Caldes T, de la Hoya M, Nevanlinna H, Muranen TA, Lesperance B, Spurdle AB, Neuhausen SL, Ding YC, Wang XS, Fredericksen Z, Pankratz VS, Lindor NM, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Loud JT, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Chenevix-Trench G, Couch FJ, Simard J, Easton DF. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast cancer research : BCR 2012; 14(1):R33
  • Hampras SS, Nesline M, Wallace PK, Odunsi K, Furlani N, Davis W, Moysich KB. Predictors of immunosuppressive regulatory T lymphocytes in healthy women. Journal of cancer epidemiology 2012; 2012 :191090
  • Raffin C, Redjimi N, Odunsi K, Valmori D, Ayyoub M. Natural CXCR3+FOXP3+Treg selectively accumulate in human ovarian carcinomas to control type I immunity. Journal of immunology (Baltimore, Md. : 1950) 2012; 188:127.27